X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PIRAMAL ENTERPRISES AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 14.8 9.1 162.4% View Chart
P/BV x 3.8 3.0 126.5% View Chart
Dividend Yield % 0.4 0.8 50.7%  

Financials

 AUROBINDO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
PIRAMAL ENTERPRISES
Mar-17
AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs8952,095 42.7%   
Low Rs6221,025 60.7%   
Sales per share (Unadj.) Rs254.6492.8 51.7%  
Earnings per share (Unadj.) Rs39.372.6 54.1%  
Cash flow per share (Unadj.) Rs46.694.7 49.2%  
Dividends per share (Unadj.) Rs2.5021.00 11.9%  
Dividend yield (eoy) %0.31.3 24.5%  
Book value per share (Unadj.) Rs160.0862.5 18.5%  
Shares outstanding (eoy) m585.88172.56 339.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.2 94.1%   
Avg P/E ratio x19.321.5 89.8%  
P/CF ratio (eoy) x16.316.5 98.8%  
Price / Book Value ratio x4.71.8 262.1%  
Dividend payout %6.428.9 22.0%   
Avg Mkt Cap Rs m444,390269,194 165.1%   
No. of employees `00014.04.0 348.4%   
Total wages/salary Rs m17,67817,939 98.5%   
Avg. sales/employee Rs Th10,667.821,190.3 50.3%   
Avg. wages/employee Rs Th1,264.34,470.1 28.3%   
Avg. net profit/employee Rs Th1,645.83,120.0 52.8%   
INCOME DATA
Net Sales Rs m149,15785,037 175.4%  
Other income Rs m1,1592,338 49.6%   
Total revenues Rs m150,31687,374 172.0%   
Gross profit Rs m34,34334,991 98.1%  
Depreciation Rs m4,2763,817 112.0%   
Interest Rs m66720,310 3.3%   
Profit before tax Rs m30,55813,202 231.5%   
Minority Interest Rs m501,699 3.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m7,5972,281 333.0%   
Profit after tax Rs m23,01212,520 183.8%  
Gross profit margin %23.041.1 56.0%  
Effective tax rate %24.917.3 143.9%   
Net profit margin %15.414.7 104.8%  
BALANCE SHEET DATA
Current assets Rs m92,06287,590 105.1%   
Current liabilities Rs m66,223185,578 35.7%   
Net working cap to sales %17.3-115.2 -15.0%  
Current ratio x1.40.5 294.5%  
Inventory Days Days10631 341.4%  
Debtors Days Days6848 142.3%  
Net fixed assets Rs m62,919108,523 58.0%   
Share capital Rs m586345 169.8%   
"Free" reserves Rs m93,133148,481 62.7%   
Net worth Rs m93,719148,826 63.0%   
Long term debt Rs m1,814144,957 1.3%   
Total assets Rs m162,494482,394 33.7%  
Interest coverage x46.81.7 2,836.3%   
Debt to equity ratio x01.0 2.0%  
Sales to assets ratio x0.90.2 520.7%   
Return on assets %14.66.8 214.1%  
Return on equity %24.68.4 291.9%  
Return on capital %32.712.0 273.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83815,001 505.6%   
Fx outflow Rs m30,2245,150 586.9%   
Net fx Rs m45,6139,851 463.0%   
CASH FLOW
From Operations Rs m32,786-100,393 -32.7%  
From Investments Rs m-17,870-24,202 73.8%  
From Financial Activity Rs m-19,153135,705 -14.1%  
Net Cashflow Rs m-4,23911,110 -38.2%  

Share Holding

Indian Promoters % 54.1 52.9 102.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 4.0 198.8%  
FIIs % 27.7 26.6 104.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 16.5 61.8%  
Shareholders   69,601 93,274 74.6%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS